Literature DB >> 1911605

Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre-eclampsia and intrauterine growth retardation.

S Bewley1, D Cooper, S Campbell.   

Abstract

OBJECTIVE: To assess the screening properties of a mid-trimester uteroplacental Doppler scan in a normal unselected population.
DESIGN: A cross-sectional study measuring an averaged resistance index (AVRI) from four sites (left and right uterine and arcuate arteries) with continuous wave Doppler ultrasound.
SETTING: Routine booking ultrasound, King's College Hospital, London.
SUBJECTS: 977 women at 16-24 weeks gestation. MAIN OUTCOME MEASURES: Intrauterine death, birthweight, pregnancy-induced hypertension (PIH), antepartum haemorrhage.
RESULTS: There was a 96.5% follow-up. Pregnancies with high AVRI values had a higher prevalence of proteinuric hypertension, placental abruption, small-for-gestational-age babies, and fetal loss. When AVRI was greater than 95th centile, the overall risk of pregnancy complications was 67%, and the risk of a severe complication was 25%. However, the sensitivity of the test for these complications was only 13% and 21% respectively. The risk for an individual woman with a high AVRI of developing a complication was increased by up to 9.8 times.
CONCLUSION: Although Doppler screening does detect a unifying defect leading to perinatal death, pre-eclampsia, growth retardation and placental abruption, the predictive values do not yet justify its introduction as a routine test.

Entities:  

Mesh:

Year:  1991        PMID: 1911605     DOI: 10.1111/j.1471-0528.1991.tb13508.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  8 in total

1.  Aspirin therapy in preeclampsia: more questions than answers.

Authors:  Bello Shaibu Oricha
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

2.  Uterine Artery Notching on Color Doppler Ultrasound and Roll over Test in Prediction of Pregnancy Induced Hypertension.

Authors:  Sujata Sharma; Sohan Singh; Uma Gujral; Upasana Oberoi; Rajwinder Kaur
Journal:  J Obstet Gynaecol India       Date:  2012-02-14

3.  Doppler and fetal growth retardation.

Authors:  R B Beattie; M J Whittle
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

4.  Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension?

Authors:  Jimmy Espinoza; Juan Pedro Kusanovic; Ray Bahado-Singh; Maria Teresa Gervasi; Roberto Romero; Wesley Lee; Edi Vaisbuch; Shali Mazaki-Tovi; Pooja Mittal; Francesca Gotsch; Offer Erez; Ricardo Gomez; Lami Yeo; Sonia S Hassan
Journal:  J Ultrasound Med       Date:  2010-07       Impact factor: 2.153

5.  Uteroplacental and Fetal 4D Flow MRI in the Pregnant Rhesus Macaque.

Authors:  Jacob A Macdonald; Philip A Corrado; Sydney M Nguyen; Kevin M Johnson; Christopher J Francois; Ronald R Magness; Dinesh M Shah; Thaddeus G Golos; Oliver Wieben
Journal:  J Magn Reson Imaging       Date:  2018-08-13       Impact factor: 4.813

6.  The Role of Uterine and Umbilical Arterial Doppler in High-risk Pregnancy: A Prospective Observational Study from India.

Authors:  Teena Nagar; Deepak Sharma; Mukesh Choudhary; Shusheela Khoiwal; Rajendra Prasad Nagar; Aakash Pandita
Journal:  Clin Med Insights Reprod Health       Date:  2015-04-15

7.  Heme oxygenase-1 is critically involved in placentation, spiral artery remodeling, and blood pressure regulation during murine pregnancy.

Authors:  Maria L Zenclussen; Nadja Linzke; Anne Schumacher; Stefan Fest; Nicole Meyer; Pablo A Casalis; Ana C Zenclussen
Journal:  Front Pharmacol       Date:  2015-01-13       Impact factor: 5.810

8.  Study of structural changes in placenta in pregnancy-induced hypertension.

Authors:  Deepalaxmi Salmani; Suja Purushothaman; Saligrama Chikkannasetty Somashekara; Ekambaram Gnanagurudasan; Kampli Sumangaladevi; Recapu Harikishan; Muthinpala Venkateshwarareddy
Journal:  J Nat Sci Biol Med       Date:  2014-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.